Completed PHASE2 INTERVENTIONAL NCT00228969

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

Sponsor: SK Life Science, Inc.

Interventions RWJ-333369

Updated 8 times since 2017 Last updated: Aug 1, 2012 Started: Feb 28, 2005 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Refractory Epilepsy and is currently completed. SK Life Science, Inc. leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SK Life Science, Inc.

Data source: SK Life Science, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Baton Rouge, United States , Bennington, United States , Birmingham, United States , Breda, Netherlands , Budapest, Hungary , Charlottesville, United States , Chesterfield, United States , Cincinnati, United States , Ciudad de Buenos Aires, Argentina and 51 more locations